caa a22 4500 445356472 CHVBK 20180317142901.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s10072-011-0547-y doi (NATIONALLICENCE)springer-10.1007/s10072-011-0547-y Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan [Elektronische Daten] [Gianni Allais, Vincenzo Tullo, Chiara Benedetto, Dario Zava, Stefano Omboni, Gennaro Bussone] Menstrually related migraine (MRM) is a particularly difficult-to-treat pain condition, associated with substantial disability. Aim of this study was to compare the efficacy and safety of frovatriptan and zolmitriptan in the treatment of MRM attacks, analyzing data from a multicenter, randomized, double blind, cross-over study. We analyzed the subset of 76 regularly menstruating women who participated in one head-to-head multicenter, randomized, double blind, cross-over clinical trial and who took the study drugs to treat MRM attacks. In a randomized sequence, each patient received frovatriptan 2.5mg or zolmitriptan 2.5mg: after treating three episodes of migraine in no more than 3months with the first treatment, the patient had to switch to the other treatment. MRM was defined according to the criteria listed in the Appendix of the last Classification of Headache disorders of the International Headache Society. A total of 73 attacks, classified as MRM, were treated with frovatriptan and 65 with zolmitriptan. Rate of pain relief at 2h was 52% for frovatriptan and 53% for zolmitriptan (p=NS), while rate of pain free at 2h was 22 and 26% (p=NS), respectively. At 24h, 74 and 83% of frovatriptan-treated and 69 and 82% of zolmitriptan-treated patients were pain free and had pain relief, respectively (p=NS). Recurrence at 24h was significantly (p<0.05) lower with frovatriptan (15 vs. 22% zolmitriptan). Frovatriptan proved to be effective in the immediate treatment of MRM attacks, similarly to zolmitriptan, but showed lower recurrence rates, and thus a better sustained relief. The Author(s), 2011 Frovatriptan nationallicence Migraine attacks nationallicence MRM nationallicence Zolmitriptan nationallicence Allais Gianni Women's Headache Center, Department of Gynecology and Obstetrics, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy aut Tullo Vincenzo Dipartimento di Neuroscienze Cliniche, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy aut Benedetto Chiara Women's Headache Center, Department of Gynecology and Obstetrics, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy aut Zava Dario Istituto Lusofarmaco d'Italia, Milan, Italy aut Omboni Stefano Italian Institute of Telemedicine, Varese, Italy aut Bussone Gennaro Dipartimento di Neuroscienze Cliniche, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy aut Neurological Sciences Springer Milan 32(2011-05-01), 99-104 1590-1874 32<99 2011 32 10072 https://doi.org/10.1007/s10072-011-0547-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0547-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Allais Gianni Women's Headache Center, Department of Gynecology and Obstetrics, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy aut NATIONALLICENCE 700 1- Tullo Vincenzo Dipartimento di Neuroscienze Cliniche, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy aut NATIONALLICENCE 700 1- Benedetto Chiara Women's Headache Center, Department of Gynecology and Obstetrics, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy aut NATIONALLICENCE 700 1- Zava Dario Istituto Lusofarmaco d'Italia, Milan, Italy aut NATIONALLICENCE 700 1- Omboni Stefano Italian Institute of Telemedicine, Varese, Italy aut NATIONALLICENCE 700 1- Bussone Gennaro Dipartimento di Neuroscienze Cliniche, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32(2011-05-01), 99-104 1590-1874 32<99 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer